Cellectar BioSciences, Inc. (CLRB)
| Market Cap | 32.99M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -21.82M |
| Shares Out | 61.10M |
| EPS (ttm) | -0.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 560,214 |
| Open | 0.595 |
| Previous Close | 0.590 |
| Day's Range | 0.531 - 0.600 |
| 52-Week Range | 0.530 - 2.980 |
| Beta | 1.56 |
| Analysts | Buy |
| Price Target | 5.58 (+933.3%) |
| Earnings Date | n/a |
About CLRB
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) Waldenstrom's macroglobulinemia (WM) and B-cell malignancies; and Phase IIB clinical study in r/r multiple myeloma (MM) patients, as well as Phase I study for various pediatric cancers, R/R head and neck cancers, and R/R MM. The company ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for CLRB stock is "Buy." The 12-month stock price forecast is 5.58, which is an increase of 933.33% from the latest price.
News
Ride on Rising P/E Investing With These 5 Top-Ranked Stocks
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Cellectar to Participate in Fireside Chat at the H.C. Wainwright Bioconnect Conference
FLORHAM PARK, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializat...
Cellectar Presented Data from its Ongoing Phase 2 CLOVER-1 Study of Iopofosine I-131 at the 63rd ASH Annual Meeting a...
Poster highlighted data from 11 patients with at least triple class refractory multiple myeloma
Best Penny Stocks To Buy? 5 To Watch With Potential Catalysts This Week
5 penny stocks to watch this week The post Best Penny Stocks To Buy? 5 To Watch With Potential Catalysts This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Cellectar Biosciences Announces Poster Presentation at the 63rd American Society for Hematology Annual Meeting and Ex...
FLORHAM PARK, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializat...
Cellectar's Iopofosine I-131 Exhibits Signals of Efficacy in Phase I Study for Pediatric Brain and Solid Tumors
FLORHAM PARK, N.J., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializat...
Cellectar Reports Financial Results for the Third Quarter 2021 and Provides a Corporate Update
FLORHAM PARK, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of targeted dru...
Cellectar Appoints Laurence Reilly, M.D., LL.M Interim Chief Medical Officer
Successful track record of developing and advancing oncology clinical programs through regulatory approval Successful track record of developing and advancing oncology clinical programs through regulato...
Cellectar Bio's Iopofosine Data Shows Favorable Safety Profile In Head & Neck Cancer
Cellectar Biosciences Inc (NASDAQ: CLRB) has completed part A portion of a safety and tolerability study of iopofosine I-131 (iopofosine) in combination with external beam radiation (EBRT) in relapsed o...
Cellectar to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
FLORHAM PARK, N.J., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for t...
Cellectar Receives $2M NIH Grant For Rare Lymphoma Study
Cellectar Biosciences Inc (NASDAQ: CLRB) has received a peer-reviewed National Institutes of Health (NIH) Phase II Small Business Innovation Research (SBIR) grant of approximately $2 million from the Na...
Cellectar Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom's ...
FLORHAM PARK, N.J., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for th...
Cellectar Announces Manufacturing and Supply Agreement with Evergreen Theragnostics for CLR-131, now known as iopofos...
Evergreen to provide clinical and commercial supply of iopofosine I-131 (also known as CLR 131)
Cellectar Reports Financial Results for the Second Quarter 2021 and Provides a Corporate Update
FLORHAM PARK, N.J., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for th...
Cellectar Announces Expansion of Ongoing Collaboration Agreement with IntoCell Inc.
Preclinical Data Supports Further Development of Multiple Novel Phospholipid Drug Conjugates (PDCs) Preclinical Data Supports Further Development of Multiple Novel Phospholipid Drug Conjugates (PDCs)
Cellectar, LegoChemBio Team Up To Develop Phospholipid Drug Conjugates For Solid Tumors
Cellectar Biosciences Inc (NASDAQ: CLRB) has collaborated with LegoChemBio to develop and commercialize phospholipid drug conjugates (PDCs). Under the agreement, the two companies have the option to joi...
Cellectar Announces a Co-Development and Commercialization Collaboration with LegoChemBio for New Small Molecule Phos...
Development of Multiple Novel PDCs Development of Multiple Novel PDCs
Cellectar to Participate in the Ladenburg Thalmann 2021 Virtual Healthcare Conference
FLORHAM PARK, N.J., July 08, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for th...
Cellectar Announces the Election of Dr. Asher Alban Chanan-Khan to Its Board of Directors
FLORHAM PARK, N.J., June 24, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for th...
Cellectar Bio Stock Drops After ASCO Presentation on White Blood Cell Cancer Therapy
Cellectar Biosciences Inc (NASDAQ: CLRB) announced updated data at the American Society of Clinical Oncology (ASCO) Annual Meeting from Phase 2 CLOVER-1 study of CLR 131 in relapsed/refractory B-cell he...
Cellectar Presents Data in Waldenstrom's Macroglobulinemia in Poster at the 2021 American Society of Clinical Oncolog...
Mean treatment free remission 1.1 years and remains ongoing
Cellectar Announces Poster Presentation of CLR 131 Data in Waldenstrom's Macroglobulinemia at the 2021 American Socie...
Management to host a KOL call with Dr. Sikandar Ailawadhi, M.D., lead investigator on June 4 at 10:00 am Management to host a KOL call with Dr. Sikandar Ailawadhi, M.D., lead investigator on June 4 at 1...
Cellectar to Participate at the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021
FLORHAM PARK, N.J., May 14, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the...
Cellectar Reports Financial Results for the First Quarter 2021 and Provides a Corporate Update
Initiated pivotal study of CLR 131 in Waldenstrom's macroglobulinemia (WM) Received European Orphan Drug Designation for CLR 131 in WM
Cellectar Strengthens Global IP Position with Phospholipid Drug Conjugate Composition of Matter Patent in Eurasia, Au...
New patent covers phospholipid-ether analogs combined with various small molecule chemotherapeutics and methods of use for PDCs™ New patent covers phospholipid-ether analogs combined with various small ...